Equities analysts expect Gamida Cell Ltd (NASDAQ:GMDA) to post earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Gamida Cell’s earnings. Gamida Cell reported earnings per share of ($14.23) during the same quarter last year, which suggests a positive year over year growth rate of 97.4%. The business is expected to report its next earnings results on Friday, February 14th.

On average, analysts expect that Gamida Cell will report full-year earnings of ($1.16) per share for the current fiscal year. For the next year, analysts forecast that the business will post earnings of ($1.31) per share. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Gamida Cell.

Gamida Cell (NASDAQ:GMDA) last released its earnings results on Tuesday, August 6th. The company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.32).

GMDA has been the subject of a number of research reports. Zacks Investment Research raised Gamida Cell from a “hold” rating to a “buy” rating and set a $4.00 target price for the company in a report on Monday, August 12th. Oppenheimer set a $18.00 target price on Gamida Cell and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, ValuEngine raised Gamida Cell from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Seven equities research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus price target of $16.50.

Shares of Gamida Cell stock traded down $0.13 on Wednesday, reaching $3.01. 100 shares of the stock were exchanged, compared to its average volume of 21,977. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.23. Gamida Cell has a twelve month low of $2.97 and a twelve month high of $15.41. The firm has a market capitalization of $78.72 million and a price-to-earnings ratio of -0.29. The business has a 50 day moving average price of $4.21 and a two-hundred day moving average price of $8.45.

A number of hedge funds have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. purchased a new position in Gamida Cell during the first quarter valued at approximately $53,000. Norges Bank purchased a new position in Gamida Cell during the fourth quarter valued at approximately $88,000. Royal Bank of Canada purchased a new position in Gamida Cell during the second quarter valued at approximately $71,000. Millennium Management LLC purchased a new position in Gamida Cell during the fourth quarter valued at approximately $210,000. Finally, Bank Hapoalim BM purchased a new position in Gamida Cell during the second quarter valued at approximately $195,000. Institutional investors own 13.25% of the company’s stock.

About Gamida Cell

Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.

Recommended Story: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Gamida Cell (GMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gamida Cell (NASDAQ:GMDA)

Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.